Introduction

On January 14, 2025, the State Administration for Market Regulation issued the Compliance Guidelines for Pharmaceutical Enterprises on Preventing Commercial Bribery Risks (hereinafter the "Compliance Guidelines"), effective from the date of issuance. As China's first compliance guidance document formulated by a regulatory authority specifically addressing commercial bribery risks in the pharmaceutical field, the Compliance Guidelines, in four chapters and forty-nine articles, subdivides commercial bribery risks of pharmaceutical enterprises into nine categories of scenarios: academic visits and exchanges, business receptions, consulting services, outsourced services, discounts, allowances and commissions, donations, sponsorships and funding, free provision of medical equipment, clinical research, and retail terminal sales. The issuance of the Compliance Guidelines signals a shift in anti-commercial-bribery compliance regulation in the pharmaceutical field from post-hoc enforcement to ex-ante prevention, and reflects an orientation from case-by-case investigation toward systemic governance.

At the same time, the criminal regulatory level is also tightening in parallel. On April 10, 2026, the Interpretation of the Supreme People's Court and the Supreme People's Procuratorate on Several Issues Concerning the Application of Law in Handling Criminal Cases of Embezzlement and Bribery (II) (Fa Shi [2026] No. 6, hereinafter the "Interpretation (II)") was issued, effective from May 1, 2026. For the medical industry, on the one hand, the Interpretation (II) expressly lists "offering bribes in the fields of ecological environment, finance, work safety, food and drugs, disaster prevention and relief, social security, education, medical care and other fields, and carrying out illegal and criminal activities" as circumstances of "seriousness"; on the other hand, Article 8 of the Interpretation (II) provides that the conviction and sentencing standards for the crime of accepting bribes by non-state functionaries and the crime of offering bribes to non-state functionaries shall respectively refer to those for the crime of accepting bribes and the crime of offering bribes (the crime of offering bribes by a unit), so the threshold amount for criminalization of accepting kickbacks is correspondingly lowered to 30,000 yuan, and the substantive standard for criminal accountability in the medical field is markedly tightened. It can be said that the Compliance Guidelines and the Interpretation (II) echo each other at the two levels of administrative regulation and criminal accountability, jointly constituting the current dual-layer regulatory framework for anti-commercial-bribery compliance of medical enterprises.

Under this dual-layer framework, a more specific and sharper question emerges: when a medical enterprise is scrutinized by review authorities over commercial bribery issues, is what it faces a substantive obstacle to listing, or a procedural risk that can be resolved through information disclosure and compliance rectification? How should the boundary between academic promotion and kickback sales be drawn? These questions directly bear on the success or failure of an enterprise's capital market path. This article addresses the above questions, discussing the boundary between unit and individual criminal liability from the perspective of subject distinction and attribution of responsibility, then setting out the high-incidence stages of commercial bribery in medical enterprises that regulators focus on, and finally proposing anti-commercial-bribery compliance planning.

01. Subject Distinction and Attribution of Responsibility for Commercial Bribery in the Medical Industry

In practice, commercial bribery in the medical industry often first manifests as the individual conduct of sales personnel. However, the characterization of individual conduct and unit conduct differs greatly in legal liability, especially after the Interpretation (II) clarified the criteria for determining unit bribery; this distinction directly bears on the ultimate attribution of responsibility.

(1) Distinction Between Bribery by Individual Employees and Unit Bribery

The key to distinguishing bribery by individual employees from unit bribery lies in whether the conduct reflects the will of the unit and whether the illegal gains belong to the unit. Article 16 of the Interpretation (II) gives a clear definition: the crime of unit bribery is established only if two elements are present: "a collective decision of the unit or a decision by the actual controller or the person in charge" and "the illegal gains belong to the unit." Conversely, if the actor, although holding a position in the unit, decides on the bribery personally and the illegal gains also belong to the individual, it shall be punished as individual bribery; if the property of the unit and the individual is commingled and the benefits obtained from the bribery actually belong to the individual, it shall likewise be determined as individual bribery.

This distinction has practical significance for medical enterprises. Pharmaceutical representatives are common perpetrators of commercial bribery in the medical industry, and whether their conduct is attributed to the individual or the unit often depends on the enterprise's organizational form and management methods. When a pharmaceutical representative's remuneration is directly linked to sales performance, his or her "kickback sales" conduct is more likely to be found to reflect the unit's will and to serve the unit's sales interests, thereby elevating individual conduct to unit conduct and exposing the enterprise itself to the criminal risk of unit bribery. In this regard, Article 11 of the Compliance Guidelines requires that "sales personnel and other personnel shall not participate in academic visits and exchanges," and Article 13 "prohibits pharmaceutical enterprises from assigning sales tasks to pharmaceutical representatives and medical device academic promotion personnel, or requiring them to carry out sales activities such as collecting payments and handling purchase and sales invoices," drawing compliance boundaries for enterprises from the perspective of separation of duties.

(2) Actual Controller's Acquiescence and Proof of Unit Will

In determining unit bribery, proof of the unit's will is key to attributing responsibility. In practice, enterprises often argue that the conduct at issue was the personal act of sales personnel and that the unit was unaware. However, under the standard established by Article 16 of the Interpretation (II), unit bribery may be found as long as it can be proven that bribes were offered to state functionaries to obtain improper benefits, the bribery was decided by the actual controller or the person in charge, and the illegal gains belonged to the unit. It is noteworthy that in judicial practice, the finding of a "decision" is not limited to active instruction; passive tolerance and knowing non-investigation of long-term, widespread illegal conduct by the sales force may also be found to reflect the unit's will. This means that the defense of unit unawareness has become significantly more difficult; if an enterprise cannot prove that it has established an effective internal control mechanism and actually implemented it, its tolerance of sales force violations will be hard to explain reasonably, and management's passive tolerance of long-term, widespread "kickback sales" conduct may well become indirect evidence of the unit's will.

The Compliance Guidelines advocate that enterprises establish a top-down compliance management system, clarify the responsible body and responsible persons for commercial bribery risk management, establish risk identification, assessment and handling mechanisms, and embed compliance requirements into business processes. This system-building is both a means of ex-ante prevention and important evidence ex post that the unit lacked intent to bribe. The establishment and operation of a compliance system thus acquires evidentiary significance beyond risk prevention and control.

02. High-Incidence Stages of Commercial Bribery in Medical Enterprises

Judging from the practice of A-share issuance review in recent years, review scrutiny of commercial bribery issues in medical enterprises shows a clear concentration in high-incidence stages. The following, in light of representative inquiry cases from the past two years, analyzes the core points of focus of review authorities on commercial bribery.

As to channels and related parties, review authorities focus on the authenticity of the enterprise's sales channels and whether related parties have borne improper sales costs on the enterprise's behalf. Take Klarity (920072, listed in June 2026) as an example: the company is a medical device enterprise, and its largest customer, US Klarity, is a company in which it holds a 40% equity interest and is also its largest overseas distributor. Both rounds of inquiries in its listing review asked about the authenticity and fairness of sales to US Klarity and required the issuer to explain whether US Klarity's "relevant retained gross profit was substantively used to carry out sales activities, whether funds flowed out to customer-related entities, and whether commercial bribery existed," and "in light of the year-by-year investment losses, explain whether there was any use of non-arm's-length transactions with US Klarity to adjust the issuer's performance." Regulators focus on whether enterprises build off-balance-sheet sales channels through overseas or related entities, transferring potential commercial bribery costs outside the issuer's consolidated statements.

Core Medical (under review) is the first innovative medical device enterprise accepted after the restart of the fifth set of listing standards of the STAR Market; both rounds of inquiries asked about its sales model and distributor issues, requiring it to explain "the extent to which distributors' procurement scale from the issuer matches their own business scale, whether distributors exclusively sell the issuer's products, comparison with comparable companies in the same industry, and whether the above distributors have any related-party relationship, other special relationship or interest arrangement with the company and its related parties," as well as "whether the issuer, distributors and promotion service providers engaged in commercial bribery in the course of product sales and market promotion, whether they were thereby subject to administrative penalties or criminal sanctions, and whether this constitutes a major violation of laws and regulations."

(2) Authenticity and Reasonableness of Selling Expenses and Promotion Expenses

Selling expenses and promotion expenses are the area where commercial bribery issues of medical enterprises are most concentrated, and also the stage with the densest review inquiries. Review authorities' focus at this stage is reflected in the authenticity and reasonableness of expenses incurred under names such as "academic promotion."

Anshi Biology (under review) focuses on anti-tumor innovative drugs; during the reporting period, while revenue grew rapidly, business entertainment expenses and academic conference expenses multiplied year on year. In the first round of review inquiries, the issuer was required to explain: "whether the composition and proportion of the company's selling expenses differ significantly from comparable companies in the same industry, and whether it has established internal control systems to prevent commercial bribery, benefit transfer and other conduct and the effectiveness of their operation." Regarding the substantially increased academic conference expenses, business entertainment expenses, travel expenses and business promotion expenses, it was also required to "analyze the reasonableness of the number of times and the amount per occasion in light of industry practice and the company's development."

Beixin Life (688712, listed in February 2026) focuses on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases. In the first round of inquiries, it was required to explain "the frequency of various publicity and promotion activities and academic conferences, and comparison of expense expenditures with the industry average; the accounting basis and internal control measures for travel expenses and business entertainment expenses, and whether there was improper benefit transfer"; in the second round of inquiries, it was required to disclose the reasons for and reasonableness of its selling expense ratio being higher than the average level of comparable listed companies in the same industry.

Tainuo Maibo (688806, listed in July 2026) is the first innovative drug enterprise to file, be accepted and pass the review under the fifth set of listing standards of the STAR Market after their restart; regulators focused on the match between selling expense growth and revenue, requiring the company to explain the reasonableness of expense growth relative to revenue growth and whether there was excessive investment or resource misallocation.

(3) Compliance of Business Models

In the process of obtaining business, bidding and tendering is the main channel through which medical equipment and consumables enter end markets. Review authorities generally require intermediaries to verify whether the issuer's participation in bidding and tendering procedures is lawful and compliant, whether there are circumstances where bidding should have been conducted but was not, and whether there were acts of offering bribes to bidders or relevant decision-makers to obtain trading opportunities.

In specific business scenarios, the free provision of medical equipment is a scenario of common concern to both anti-commercial-bribery enforcement and issuance review. Articles 35 to 37 of the Compliance Guidelines specifically regulate this. Article 36 requires enterprises to provide equipment for reasonable uses, to specify equipment ownership in contracts, and to carefully review provision projects; Article 37 prohibits using the free provision of medical equipment to improperly obtain trading opportunities and competitive advantages, to circumvent or interfere with public bidding and procurement procedures, to influence bidding and procurement results, and to carry out illegal benefit transfer.

In categories where the "two-invoice system" is implemented, distribution tiers are compressed and circulation links reduced, so ex-factory prices and gross margins rise accordingly; whether such changes are reasonable and whether they match product competitiveness and industry practice is also a key focus of review.

(4) Verification of Off-Book, Covert Payments

The risks in each of the foregoing stages ultimately come down to the tracing and look-through verification of funds. Off-book and covert payments are the key vehicle through which commercial bribery is carried out, and are also a funding verification point requiring particular attention in the review. Review institutions typically require enterprises to explain the payment methods for selling expenses, for example: whether payments are made through traceable means such as bank transfers; whether there are off-book operations such as large cash payments or receipt of payments into personal accounts; and whether funds are extracted for use in commercial bribery by means such as issuing false invoices or fabricating services. The provisions of the Compliance Guidelines on discounts, rebates and commissions require enterprises to grant them openly and record them truthfully in the accounts, and prohibit the untruthful recording in the financial books of discounts, rebates or commissions paid or accepted. That section also reminds enterprises to avoid situations where there is no appropriate segregation of duties between the department or personnel that formulate discount and rebate standards and approval systems and the department or personnel that specifically implement them.

Taking together the stages that the review focuses on, medical enterprises may pay attention to the following aspects: at the business level, review whether equipment placement agreements and sales agreements are independent of each other and whether there are any tying clauses; at the channel level, conduct look-through verification of the qualifications, affiliate relationships and authenticity of terminal sales of distributors and promotion service providers, and pay attention to the reasonableness of changes in gross profit margin and selling expense ratio; at the financial level, intermediaries are usually required to conduct look-through verification of the fund flows of key sales personnel and related parties and other personnel; at the institutional level, enterprises should ensure the establishment and implementation of systems such as segregation of duties, truthful recording in the accounts and full-process documentation.

03. Incorporating anti-commercial-bribery compliance into the listing planning of medical enterprises

Based on the foregoing analysis, if anti-commercial-bribery compliance verification and rectification are only commenced during the listing process in response to regulatory inquiries, the enterprise will fall into the predicament of being forced into reactive responses. Therefore, it should be incorporated into the overall arrangements for listing planning and the enterprise's day-to-day compliance management.

(1) Timing and window period for compliance rectification

For the compliance rectification of commercial bribery issues, the key lies in grasping the timing of rectification. For medical enterprises planning to list, rectification should be advanced as far as possible to before the reporting period for the application. The review institutions' attention to commercial bribery issues usually takes the reporting period as the verification window; if rectification falls within the reporting period or even after its expiry, it will be difficult for the enterprise to prove that its sales model during the reporting period was compliant and that it met the listing standards and regulatory requirements.

(2) Standardization of the CSO structure

Contract sales organizations (CSOs) are an important part of the sales model of pharmaceutical enterprises and also a high-incidence area of commercial bribery risk. The risk prevention provisions of the Compliance Guidelines on outsourced services remind pharmaceutical enterprises to establish a selection and engagement mechanism, conduct compliance review of outsourced service providers and encourage due diligence on them, recommend formulating a negative list in contracts, supervise the service conduct of CSOs, and settle accounts according to genuine service results. These compliance requirements, from selection and engagement onward and covering specific stages such as compliance review, contracts, supervision and settlement, provide specific guidance for enterprises planning to list in standardizing their CSO structures.

(3) The probative value of compliance system building

Compliance system building not only has an ex ante preventive function but also has important probative value. If an enterprise can establish and operate an anti-commercial-bribery compliance management system that meets the requirements of the Compliance Guidelines, this may serve as relevant evidence proving that "the entity did not have the intent to offer bribes." On this basis, enterprises may also consider introducing ISO 37001 Anti-Bribery Management System certification, using third-party certification to enhance the credibility and verifiability of the compliance system.

(4) Practical difficulties in implementing the Compliance Guidelines

There are several key points and difficulties in the practical implementation of the Compliance Guidelines. The first is the segregation of duties between medical representatives and sales personnel; where non-compliant situations existed previously, enterprises need to make systematic adjustments to their organizational structure, assessment mechanisms and remuneration systems. The second is proving the authenticity of consulting services; enterprises should establish a full-process documentation mechanism for the initiation, execution and acceptance of consulting services, avoiding arrangements that are nominally consulting but actually promotion. The third is grasping the boundaries of sponsorship activities; enterprises should distinguish legitimate academic sponsorship from disguised transfer of benefits, ensuring that sponsorship activities have independent academic value and reasonable consideration.

(5) The practical impact of the Interpretation (II) on enterprises

The entry into force of the Interpretation (II) imposes higher requirements on the compliance planning of medical enterprises. On the one hand, provisions such as the clarification of the conviction thresholds for entity bribery and the inclusion of bribery in the medical field within the category of "serious circumstances" raise the baseline requirements for enterprise sales compliance; on the other hand, the standard for determining entity will under Article 16 requires enterprises to establish an effective compliance defense line at the institutional level, preventing management from being found to have "tacitly consented" and thus suspected of entity bribery. Therefore, in listing planning, enterprises should move the focus of anti-commercial-bribery compliance forward to the establishment of an effective compliance system, using institutionalized compliance management to block the path of finding entity will.

04. Conclusion

Under the dual-layer regulatory framework jointly constituted by the Compliance Guidelines and the Interpretation (II), the commercial bribery issue of medical enterprises has evolved from a purely administrative compliance matter into a key variable affecting enterprises' capital market paths and criminal risk prevention. As regards the distinction of subjects, the boundary between bribery by individual employees and entity bribery, after the Interpretation (II) clarified the standard for determining entity will, imposes higher requirements on enterprises' internal control systems. At the practical level, medical enterprises planning to list should advance anti-commercial-bribery compliance to before the reporting period and, through means such as standardizing the CSO structure, building compliance systems and implementing the Compliance Guidelines, build a compliance defense line that can withstand review scrutiny and embark on a listing path that is steady and far-reaching.

Questions and answers

What is the criminalization threshold for accepting kickbacks in the medical field under the Interpretation (II)?

The threshold is 30,000 yuan. Article 8 of the Interpretation (II) provides that the conviction and sentencing standards for accepting bribes by non-state functionaries and offering bribes to non-state functionaries shall refer to those for the crime of accepting bribes and the crime of offering bribes, thereby lowering the threshold amount for criminalization of accepting kickbacks to 30,000 yuan.

How does the Interpretation (II) distinguish unit bribery from individual employee bribery?

Article 16 of the Interpretation (II) requires two elements for unit bribery: a collective decision of the unit or a decision by the actual controller or person in charge, and illegal gains belonging to the unit. If the actor decides personally and gains belong to the individual, or if unit and individual property are commingled and benefits actually belong to the individual, it is individual bribery.

What stages of commercial bribery do review authorities focus on for medical enterprises seeking A-share listing?

Review authorities focus on four high-incidence stages: benefit transfer through channels and related parties, authenticity and reasonableness of selling and promotion expenses, compliance of business models including bidding and free equipment provision, and verification of off-book or covert payments. These stages are drawn from recent A-share issuance review inquiries.

When should a medical enterprise complete anti-commercial-bribery compliance rectification before listing?

Rectification should be advanced as far as possible to before the reporting period for the listing application. Review institutions usually take the reporting period as the verification window; if rectification falls within or after the reporting period, it will be difficult for the enterprise to prove that its sales model during the reporting period was compliant and met listing standards.

What is the probative value of building an anti-commercial-bribery compliance system for a medical enterprise?

A compliance system meeting the Compliance Guidelines may serve as relevant evidence proving that the entity did not have the intent to offer bribes. Enterprises may also consider ISO 37001 Anti-Bribery Management System certification to enhance the credibility and verifiability of the compliance system, which helps block a finding of unit will.

Laws and cases cited

Judicial interpretations

  • Interpretation of the Supreme People's Court and the Supreme People's Procuratorate on Several Issues Concerning the Application of Law in Handling Criminal Cases of Embezzlement and Bribery (II)
  • Article 16 of the Interpretation (II)
  • Article 8 of the Interpretation (II)

Policy documents

  • Compliance Guidelines for Pharmaceutical Enterprises on Preventing Commercial Bribery Risks
  • Article 11 of the Compliance Guidelines
  • Articles 35 to 37 of the Compliance Guidelines

Standards

  • ISO 37001 Anti-Bribery Management System